1 report

  • Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers
  • Kiadis Pharma Raises USD1 Million in Private Placement of Shares

Summary Kiadis Pharma NV (Kiadis) is a biopharmaceutical company that researches, develops and markets cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders.The company offers cellular products including ATIR101 and ATIR201 for infusion. Its ATIR101 offers risks and limitations...

  • Cancer
  • Netherlands
  • United States
  • World
  • Kiadis Pharma N.V.